Could a traditional chinese medicine compound boost prostate cancer treatment?

NCT ID NCT07163910

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding homoharringtonine (a drug from a Chinese evergreen plant) to standard hormone therapy before prostate removal can improve outcomes for men with high-risk or advanced prostate cancer. About 93 participants will receive the drug combination before surgery, and researchers will measure how many achieve a complete or major response. The goal is to find a more effective neoadjuvant treatment for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
homoharringtonine (a plant-derived chemotherapy drug) combined with androgen deprivation therapy (hormone therapy)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option to improve outcomes for men with advanced or high-risk prostate cancer.
What could go wrong
This is a small, early-phase trial (Phase 2) with no control group, so results may not prove effectiveness. The drug can cause side effects like bone marrow suppression and heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongda Hospital

    RECRUITING

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.